Execution risk in product approvals for Pune facility
Ramp-up of SPL Infusion depends on obtaining approvals for 23-24 products; delays could impact revenue targets.
high · management_commentarySanjivani Paranteral Ltd — Q3 FY26
Sanjivani Paranteral delivered a strong Q3 FY26 with consolidated revenue of ₹22.1 crore (+27.1% YoY) and EBITDA margin expansion of 230 bps to 18.5%, driven by favorable produc...
bullish
high
✓ Verified against BSE filing
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
Margin volatility from product mix shifts
Management acknowledged that quarterly margins can fluctuate due to product mix, which may affect predictability.
medium · analyst_questionGeopolitical and logistics disruptions
Past logistics issues due to geopolitical tensions have been resolved, but any recurrence could impact export shipments.
medium · management_commentaryLow promoter shareholding
An analyst raised concern about promoter shareholding being low; management indicated gradual increases but no specific target.
low · analyst_question